Sandoz Group (OTCMKTS:SDZNY) Trading 0.4% Higher – Time to Buy?

Shares of Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) were up 0.4% on Wednesday . The company traded as high as $80.8099 and last traded at $80.49. Approximately 14,264 shares changed hands during trading, a decline of 21% from the average daily volume of 17,995 shares. The stock had previously closed at $80.17.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SDZNY shares. Royal Bank Of Canada cut Sandoz Group from a “moderate buy” rating to a “hold” rating in a research note on Monday, March 23rd. The Goldman Sachs Group raised Sandoz Group to a “strong-buy” rating in a research note on Wednesday, April 1st. Finally, Barclays upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Three investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Strong Buy”.

Sandoz Group Stock Performance

The company has a quick ratio of 0.77, a current ratio of 1.18 and a debt-to-equity ratio of 0.53. The stock’s fifty day simple moving average is $84.48 and its two-hundred day simple moving average is $81.93.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.